Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
BDBiodesix, Inc. logo

Biodesix, Inc. (BDSX)

NASDAQ Global Market · Currency in USD
$21.18 ▼ -2.76 (-11.53%)
At close: Oct 23, 4:00 PM ET. Market closed.
$21.05 ▼ -0.13 (-0.61%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$23.94
Open
$23.04
Day's Range
$21.11 – $23.39
52 Week Range
$5.26 – $31.97
Volume
139,718
Avg. Volume
100,005
Market Cap
$172.41M
Beta (5Y Monthly)
0.55
PE Ratio (TTM)
--
EPS (TTM)
-$2.70
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$35.00

Profile: Biodesix, Inc.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Full-time employees
334
CEO
Scott Hutton

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.75 · Revenue est. $27.56M
DateEst.Actual
Aug 5, 2026-$0.90-$0.71Beat
May 4, 2026-$1.26-$0.81Beat
Feb 26, 2026-$1.05-$0.49Beat
Nov 3, 2025-$1.60-$1.16Beat
Aug 7, 2025-$1.40-$1.60Miss
May 13, 2025-$1.40-$1.60Miss

Analyst view

Consensus price target
$35.00 ▲ +65.3%
Range $32.00 – $38.00
Rating: Buy
Buy 89% · Hold 11% · Sell 0%

Get free alerts on BDSX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.